Le Lézard
Classified in: Science and technology
Subjects: DIS, DEI

Synterex Leadership Joins the Ranks of Regulatory Affairs Certified Professionals


DEDHAM, Mass., Dec. 26, 2021 /PRNewswire-PRWeb/ -- The Regulatory Affairs Professional Society (RAPS) announced in December that 108 professionals passed the Regulatory Affairs Certification (RAC) exam in the summer testing window, one of whom was Synterex President Jeanette Towles. Passing the exam conferred the RAC-Drugs credential, the leading credential for regulatory professionals in the drugs healthcare product sector.

"This certification solidifies our commitment to regulatory excellence here at Synterex and formalizes the many regulatory successes we have shared in over the years," said Synterex President Jeanette Towles. "I am delighted to join the ranks of many of our other Synterex associates in obtaining this important certification, and I would like to thank the regulatory professionals over the years who took the time to help me develop a strategic mindset."

The RAC exams are rigorous, and to pass them requires an intimate knowledge of healthcare product regulations as well as the critical thinking skills to aptly apply this knowledge to various scenarios in regulatory affairs. RAC-credentialed professionals are among the current and rising leaders in the regulatory profession.

For more information on Synterex and its leadership, visit: http://www.synterex.com.

About Synterex, Inc.:
Synterex is a WBENC-Certified Women's Business Enterprise and disability-owned clinical and regulatory consulting firm that provides clinical development solutions.

Delivering quality regulatory documentation requires navigating an evolving landscape influenced by regulators, research committees, healthcare professionals, and?most importantly?the scientific method itself.

At Synterex, we forge lasting and meaningful relationships that flex with the dynamic nature of science and technology.
Our staffers are seasoned and dedicated, with extensive experience doing the work hands-on as well as building and leading teams. We are committed to applying our years of experience and current subject matter and technical knowledge to help clients deliver important new therapies to patients in an expedient manner.

About RAPS:
The Regulatory Affairs Professionals Society (RAPS) is the largest global organization of and for those involved with the regulation of healthcare and related products, including medical devices, pharmaceuticals, biologics and nutritional products. Founded in 1976, RAPS helped establish the regulatory profession and continues to actively support the professional and lead the profession as a neutral, non-lobbying nonprofit organization. RAPS offers education and training, professional standards, publications, research, knowledge sharing, networking, career development opportunities and other valuable resources, including Regulatory Affairs Certification (RAC). The RAC is the only post-academic professional credential to recognize regulatory excellence. RAPS is headquartered in suburban Washington, DC, with chapters and affiliates worldwide.

Media Contact

Jeanette Towles, Synterex, +1 7812855399, [email protected]

Twitter

 

SOURCE Synterex


These press releases may also interest you

at 20:14
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology...

at 20:00
SUNRATE, an intelligent global payment and treasury management platform today announced it has joined Mastercard Priceless Planet Coalition in support of fighting climate change through funding the restoration of 100 million trees. This announcement...

at 20:00
The advanced laser and plasma solution provider from Taiwan, E&R Engineering Corp., is confirmed to attend the feast in Semiconductor industry, Semicon SEA 2024, held in Kuala Lumpur, Malaysia. With the 30-year dedication in the semiconductor...

at 17:20
The Phase IIa COURSE trial was a proof-of-concept study in people with moderate to very severe chronic obstructive pulmonary disease (COPD) with a broad range of blood eosinophil counts (BEC) and irrespective of emphysema, chronic bronchitis or...

at 14:15
Endeavor BioMedicines, a clinical-stage biotechnology company developing medicines with the potential to deliver transformational clinical benefits to patients with life-threatening diseases, announced results from a completed Phase 2a clinical trial...

at 12:20
Savara Inc. (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, presented a poster at the American Thoracic Society (ATS) 2024 International Conference that is taking place May 17-22, 2024, in San Diego,...



News published on and distributed by: